The Research Council of Norway has granted $2.5m to Clavis Pharma to develop a flow cytometry method for the detection and quantification of human Equilibrative Nucleoside Transporter (hENT1) in patients suffering from acute myeloid leukaemia (AML).
The hENT1 flow cytometry project will be a collaborative effort between scientists at Clavis Pharma and international experts in the field of cancer diagnostics.
The objective of the research is to select sub-population of AML patients who can benefit most from Clavis Pharma’s anti-cancer drug elacytarabine.
Clavis Pharma CEO Olav Hellebo said this grant helps them to complete the final phase of their biomarker development programme.
Clavis Pharma patented drugs are made by using its Lipid Vector Technology (LVT) chemistry.
Clavis Pharma’s drug candidates that are in development include Elacytarabine to treat leukaemia, CP-4126 to treat pancreatic cancer and CP-4200 to treat myelodysplastic syndrome (MDS).